Hoth Therapeutics Reports Positive Preclinical Data For Alzheimer's Disease Drug Candidate HT-ALZ

(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Wednesday reported positive results from the preclinical study of its lead drug candidate HT-ALZ for the treatment of Alzheimer's disease.

HT-ALZ has shown significant cognitive and behavioral benefits in APP/PS1 mouse models of Alzheimer's disease. The study demonstrated that chronic oral administration of HT-ALZ led to marked improvement in memory, reduction of anxiety-like behavior, and enhanced sensorimotor gating, all without impairing motor function. Additionally, treatment with HT-ALZ led to a rapid 15 percent reduction in brain interstitial fluid Aß levels.

The company plans to advance HT-ALZ into clinical development.